Khurana Kiranpreet K, Grane Ronald, Borden Ernest C, Klein Eric A
Glickman Urological & Kidney Institute, Cleveland, Ohio, USA.
Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.
Curr Urol. 2013 Nov;7(2):65-9. doi: 10.1159/000356251. Epub 2013 Oct 30.
Circulating tumor cells (CTC) predict overall survival in patients with metastatic prostate cancer. The objective of this study is to measure CTC before radical prostatectomy in intermediate- and high-risk prostate cancer patients.
The study accrued 12 patients and 10 provided adequate peripheral blood sample. Blood was drawn preoperatively and assayed for CTC using the CellSearch system. Patients were categorized as CTC positive (≥ 1 CTC) or CTC negative (no CTC).
Median age was 64.5 years (range 49-77 years), median prostate specific antigen was 7.4 ng/ml (range 5.7-25.7 ng/ml). Seven patients had intermediate-risk and 3 patients had high-risk prostate cancer. One patient was found to be CTC positive.
Our pilot study shows that CTC are rare in patients with clinically localized disease despite intermediate- to high-risk features. CTC may not be the optimal marker to predict prognosis or detect residual disease after radical prostatectomy.
循环肿瘤细胞（CTC）可预测转移性前列腺癌患者的总生存期。本研究的目的是在中高危前列腺癌患者行根治性前列腺切除术之前检测CTC。
本研究纳入了12例患者，其中10例提供了足够的外周血样本。术前采集血液，使用CellSearch系统检测CTC。患者被分为CTC阳性（≥1个CTC）或CTC阴性（无CTC）。
中位年龄为64.5岁（范围49 - 77岁），中位前列腺特异性抗原为7.4 ng/ml（范围5.7 - 25.7 ng/ml）。7例患者为中危前列腺癌，3例患者为高危前列腺癌。发现1例患者CTC阳性。
我们的初步研究表明，尽管具有中高危特征，但临床局限性疾病患者中CTC罕见。CTC可能不是预测根治性前列腺切除术后预后或检测残留疾病的最佳标志物。
